Rejuvenate Biomed is a clinical-stage company dedicated to the discovery and development of therapeutics to prevent or delay the onset of multiple age-related diseases. Founded in 2017, Rejuvenate Biomed is a privately-held platform and pipeline company developing safe and proprietary combination drugs that help people healthy for life. By using platform technologies, Rejuvenate Biomed identifies safe compounds that influence the aging process. Novel combination drugs are discovered that have the potential to prevent or delay the onset of multiple age-related diseases. Rejuvenate Biomed confirms prediction data in preclinical models and in clinical studies. Rejuvenate Biomed’s lead drug candidate RJx-01 is currently in Phase 1b for the treatment of sarcopenia, the progressive age-associated loss of muscle function and mass.